Lantern Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Lantern Pharma Inc. on June 13, 2024. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol LTRN. The filing was signed on June 17, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Three primary matters were submitted to a vote of security holders:
- Director Elections: All five nominees were elected to the Board of Directors to serve until the 2025 Annual Meeting. The nominees are Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, and David S. Silberstein. Significant broker non-votes (4,225,984 shares) were recorded for all director elections.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to increase the number of shares available for issuance under the 2018 Equity Incentive Plan by an additional 125,000 shares. The vote was 2,892,948 For, 128,312 Against, and 39,969 Abstain.
- Appointment of Auditors: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 7,169,506 For, 39,941 Against, and 77,766 Abstain. There were no broker non-votes on this item.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verification of the total number of shares outstanding to contextualize the voting percentages.
- Confirmation of the specific terms of the 125,000 share increase to the Equity Incentive Plan.
- Review of the full proxy statement for details on the background of the newly elected directors.
- Confirmation of the fiscal year-end date (December 31, 2024) for future financial reporting expectations.